McDonald Hopkins: Collection and handling payments under scrutiny

McDonald Hopkins

Jane Pine Wood, a specialist in health law and member of McDonald Hopkins, recently sent me the following Healthcare Alert that serves as a reminder the federal government is closely scrutinizing financial arrangements between laboratories and referring physicians.

Her email stated McDonald Hopkins put the alert together because:

[W]e are increasingly encountering situations where the laboratories and the health care providers may run afoul of federal and state fraud and abuse guidelines, particularly with respect to payments made by the laboratories to the health care providers for the collection, handling and/or processing of laboratory specimens that will be referred by the health care providers to the laboratories.

Many thanks to Ms. Wood for making this available to us.


On June 25, 2014, the Office of Inspector General (OIG) issued a special fraud alert entitled “Laboratory Payments to Referring Physicians.” The alert deals specifically with laboratories paying compensation to physicians and group practices for blood specimen collection, processing, and packaging activities, as well as the submission of patient data to a database or registry.

The Medicare and Medicaid anti-kickback statute is implicated when remuneration is paid in order to induce or reward referrals for any items or services reimbursed by a federal healthcare program. The alert cautions against arrangements that improperly take into account the volume or value of referrals that may induce a physician or physician group to use a particular laboratory or cause overutilization of testing services. The OIG highlights in this special fraud alert that certain arrangements are particularly suspect under the anti-kickback statute, including specimen collection, processing and packaging arrangements, and registry payments.


The OIG explains the risks associated with arrangements where a physician or physician group is paid by a laboratory for the collection, processing, and/or packaging of specimens. Specimen collection is reimbursed by Medicare only in certain circumstances, including where it is customary practice in the region and for that particular physician to charge for specimen collection separately. There are also separate CPT codes for processing and packaging specimens for transport to a laboratory. Since the laboratory payments to a physician or physician group for these services are often per-specimen or per-patient, the anti-kickback statute is implicated and the OIG cautions laboratories entering into these arrangements to consider, for purposes of determining fair market value, whether or not the physician is already compensated for the activity either through a bundled payment or through payments for overhead expenses. Certain characteristics that the OIG finds to be evidence that the arrangement may be unlawful include if:

  • The payments exceed fair market value, is calculated on a per-specimen or per patient method, or is offered on the condition of a certain number of orders.
  • The physician is already paid for the services by a third party, such as Medicare.
  • The payments go directly to a physician rather than the group practice that actually bears the cost of the services or where the services are performed by someone placed in the office by the laboratory.

[Continue reading]

LabCorp and BioReference Laboratories sued for missing endometrial cancer

Ms. Jacquelyn Graulty has filed a lawsuit in Louisiana against LabCorp and BioReference Laboratories in which she alleges the laboratories were negligent in "preparing, testing, reading, reviewing, analyzing, categorizing, reporting, and storing" her Pap smear and histologic slides, and this led to a delay in the diagnosis and treatment of her endometrial cancer.  Ms. Graulty's former gynecologist and medical practice are also named as defendants. Factual Allegations Ms. Graulty originally … [Continue reading]

House Oversight Committee questions credibility of witness against uropathology laboratory LabMD

House Oversight Committee logo

  The House Oversight Committee has significant concerns about the credibility of data security company Tiversa as a witness for the Federal Trade Commision (FTC) in its action against uropathology laboratory LabMD.  The Committee shared its concerns, and the reasons it developed them, in a December 2014 letter to FTC chairwoman Edith Rodriguez that was made public on February 13th. Background The FTC filed an administrative action against LabMD on August 29, 2013 after an … [Continue reading]

Laboratory supervisor’s retaliation and wrongful discharge claims against hospital survive motion to dismiss

Cindy Flick, former Laboratory Section Supervisor at Lourdes Hospital in Paducah, Kentucky, filed a lawsuit against her former employer that alleged, among other things, the hospital solicited kickbacks from Agendia, and retaliated and wrongfully discharged her after she made her concerns known to her superiors. A US District Court in Kentucky recently considered Lourdes' motion to dismiss and allowed Ms. Flick's claims that she was retaliated against, wrongfully discharged, and discouraged … [Continue reading]

Pharmacogenetics laboratory Renaissance RX faces uncertain future

Renaissance RX (Ren RX), the New Orleans-based pharmacogenetics laboratory whose founder just nine months ago said the company had experienced "intense, crazy growth", has reportedly laid off a significant number of employees after Medicare stopped reimbursing the lab for a drug reactions registry/study. Ren RX was founded in June 2012 as a simple toxicology lab with only a handful of employees.  By mid 2013, it had around a dozen employees, and, incredibly, a little over a year later Ren … [Continue reading]

Pathology Blawg News Roundup for February 13, 2015

Myriad Genetics, Quest Diagnostics settle BRCA lawsuit Myriad Genetics and Quest Diagnostics have reached a settlement that ends their legal dispute over BRCA testing. Readers will recall Quest filed a pre-emptive suit in October 2013 against Myriad, asking the court for a declaratory judgment that its new BRCA test, BRCAvantage, was not infringing on any of Myriad's BRCA patents.  Less than two weeks later, Myriad countersued, alleging Quest was infringing on its BRCA … [Continue reading]

Uropathology laboratory LabMD sues Tiversa for racketeering and conspiracy

LabMD, the Atlanta-based uropathology laboratory currently embroiled in a years-long administrative and legal fight with the Federal Trade Commission (FTC), has sued data security company Tiversa, its CEO Dr. Robert Boback, and Dr. M. Eric Johnson, alleging they engaged in a "multi-year, nationwide, continuing racketeering scheme and conspiracy" against LabMD. Background I have written about the ongoing administrative and legal battle between LabMD and the FTC numerous times, the most recent … [Continue reading]

Class action suit accuses Quest Diagnostics of being a monopoly

Blue Shield of California

A new lawsuit filed in the Northern District of California alleges Quest Diagnostics paid kickbacks to physicians, colluded with Aetna and Blue Shield of California (BSC) to suppress competition, and acquired laboratory competitors in order to achieve and maintain a monopoly on clinical diagnostic testing in northern California. Physician kickback allegations There are two relevant insurance markets at play here: the "physician billing" market in which Quest bills the referring physician for … [Continue reading]

Pathology Blawg News Roundup for February 6, 2015

Medicare Administrative Contractor Noridian issues ancillary stain draft LCD Noridian Healthcare Solutions, the Medicare Administrative Contractor (MAC) for Jurisdiction E (which includes California) and Jurisdiction F, has issued a draft local coverage determination (LCD) policy for anatomic pathology ancillary stains that is identical (as far as I can tell) to the draft LCD issued by Palmetto GBA back in late October 2014. Noridian's draft LCD does not contain the changes Palmetto made … [Continue reading]

Appellate court upholds dismissal of challenge to FTC action filed by LabMD

The Eleventh Circuit Court of Appeals has upheld the dismissal by a lower court of a challenge filed by uropathology laboratory LabMD which sought to bring an end to an administrative action filed against it by the Federal Trade Commission (FTC). Background I have written about the LabMD/FTC saga quite a bit already, and readers can refer to these posts for more info, but what follows is a brief synopsis of how we got to where we are. According to LabMD, a company called Tiversa obtained … [Continue reading]

Myriad Genetics working to end all BRCA patent infringement disputes

Myriad Genetics has settled the BRCA patent infringement lawsuits it filed against LabCorp, Invitae and Pathway Genomics, and is reportedly working to settle other pending BRCA lawsuits involving Quest Diagnostics, Ambry Genetics, GeneDx and Counsyl.  This brings to an end nearly six years of essentially continuous litigation over Myriad's BRCA patents. Background On June 13, 2013, the US Supreme Court unanimously invalidated the patents Myriad held on BRCA1 and BRCA2 on the grounds that … [Continue reading]

Palmetto GBA finalizes ancillary stain LCD over objections of the College of American Pathologists

CAP New Logo

Palmetto GBA, the Medicare Administrative contractor for the Carolinas and Virginias, has finalized its ancillary stain local coverage determination (LCD) policy over the objections of the College of American Pathologists (CAP), which had asked Palmetto to withdraw the LCD entirely. As best I can tell, the final LCD is essentially identical to the draft, with the following exceptions: Pre-ordering of ancillary stains is permissible for medical liver, kidney and neuromuscular biopsies, … [Continue reading]

United States files brief against Millennium Health appeal in urine drug testing cup suit

The United States has filed an amicus curiae (friend of the court) brief that urges the Eleventh Circuit Court of Appeals to reject the appeal filed by Millennium Health (MH) in a case in which a jury found MH violated both the Stark Law and the federal Anti-Kickback Statute (AKS) by providing free point-of-care urine drug testing (POCT) cups to physicians. I am writing about this brief because it is my understanding (although I could be wrong) this is very unusual and may be the first … [Continue reading]

Former CEO of Renaissance RX sues founder for breach of contract

Renaissance RX logo

Mr. David Guzan, the former CEO of pharmacogenetics laboratory Renaissance RX, has filed a lawsuit against Renaissance's founder, Dr. Tarun Jolly, alleging Dr. Jolly failed to transfer a 1% ownership stake in Renaissance potentially worth $2.5 million to Mr. Guzan as promised. Altogether there are a total of four claims in the suit, three of which do not involve Renaissance, but are nonetheless interesting in that they all involve money owed to Mr. Guzan by entities affiliated with Dr. … [Continue reading]

Pathology Blawg News Roundup for January 23, 2015

Physician who accepted laboratory kickbacks gets 46 months in prison Dr. Linda Rosenberg, a physician who pled guilty in February 2014 to accepting kickbacks in exchange for laboratory and radiology referrals, and for dispensing hydrocodone “outside the scope of professional practice”, has been sentenced to 46 months in prison. Dr. Rosenberg received approximately $1500 per month in sham office lease payments from an unnamed Chicago laboratory and nearly $34,000 per month from … [Continue reading]